A
WST icon

Astrantus’s West Pharmaceutical WST Stock Holding History

Astrantus’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$205K Buy
+500
New +$196K 0.34% 167

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Astrantus's WST Position: Q1 2022 in Review

Astrantus opened a new position in West Pharmaceutical (WST) in Q1 2022: 500 shares worth $205K. The stake represents 0.34% of the portfolio and ranks #167 among its holdings.

716 funds tracked by Wall St. Rank hold WST as of Q1 2022.

  • Astrantus held 500 shares of West Pharmaceutical worth $205K as of Q1 2022.
  • West Pharmaceutical was a new Astrantus position in Q1 2022.
  • West Pharmaceutical made up 0.34% of Astrantus's portfolio in Q1 2022, its #167 holding.
  • 716 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.